UA48940C2 - Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень - Google Patents

Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень

Info

Publication number
UA48940C2
UA48940C2 UA96041300A UA96041300A UA48940C2 UA 48940 C2 UA48940 C2 UA 48940C2 UA 96041300 A UA96041300 A UA 96041300A UA 96041300 A UA96041300 A UA 96041300A UA 48940 C2 UA48940 C2 UA 48940C2
Authority
UA
Ukraine
Prior art keywords
treatment
mediated diseases
mabs used
mabs
humanized
Prior art date
Application number
UA96041300A
Other languages
English (en)
Russian (ru)
Inventor
Стефен Дадлі Холмс
Мітчел Стюарт Гросс
Деніел Р. Сільвестр
Original Assignee
Смітклайн Бічам Корпорейшн
Смитклайн Бичам Корпорейшн
Смітклайн Бічам Плс
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смітклайн Бічам Корпорейшн, Смитклайн Бичам Корпорейшн, Смітклайн Бічам Плс, Смитклайн Бичам Плс filed Critical Смітклайн Бічам Корпорейшн
Publication of UA48940C2 publication Critical patent/UA48940C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Описані химерні та гуманізовані моноклональні антитіла проти ІЛ-4, які є похідними високоафінних моноклональних антитіл, фармацевтичні композиції , що містять такі антитіла та способи лікування.
UA96041300A 1993-09-07 1994-09-07 Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень UA48940C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11736693A 1993-09-07 1993-09-07
US13678393A 1993-10-14 1993-10-14
PCT/US1994/010308 WO1995007301A1 (en) 1993-09-07 1994-09-07 Recombinant il4 antibodies useful in treatment of il4 mediated disorders

Publications (1)

Publication Number Publication Date
UA48940C2 true UA48940C2 (uk) 2002-09-16

Family

ID=26815208

Family Applications (1)

Application Number Title Priority Date Filing Date
UA96041300A UA48940C2 (uk) 1993-09-07 1994-09-07 Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень

Country Status (21)

Country Link
EP (1) EP0730609B1 (uk)
JP (4) JPH09502708A (uk)
KR (1) KR100362340B1 (uk)
CN (2) CN1105728C (uk)
AP (1) AP583A (uk)
AT (1) ATE286510T1 (uk)
AU (1) AU695726B2 (uk)
BG (1) BG63549B1 (uk)
BR (1) BR9407575A (uk)
CA (1) CA2171336C (uk)
CZ (1) CZ295928B6 (uk)
DE (1) DE69434223T2 (uk)
ES (1) ES2236693T3 (uk)
FI (1) FI119733B (uk)
HU (1) HU222041B1 (uk)
NO (1) NO960956L (uk)
NZ (1) NZ274338A (uk)
PL (1) PL180125B1 (uk)
SK (1) SK285556B6 (uk)
UA (1) UA48940C2 (uk)
WO (1) WO1995007301A1 (uk)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
ES2337473T3 (es) 2004-02-19 2010-04-26 Genentech, Inc. Anticuerpos reparadores con cdr.
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2007107349A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treament of cancer
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101529253A (zh) 2006-06-21 2009-09-09 阿珀吉尼科斯有限公司 Il-4和/或il-10细胞因子在人癌症中的差异表达
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP4971872B2 (ja) 2007-05-23 2012-07-11 株式会社トプコン 眼底観察装置及びそれを制御するプログラム
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5324839B2 (ja) 2008-06-19 2013-10-23 株式会社トプコン 光画像計測装置
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102294024B (zh) * 2011-01-17 2013-03-13 广东现代农业集团研究院有限公司 一种多肽疫苗及其制备方法
EP3514181A1 (en) * 2015-02-24 2019-07-24 Academia Sinica A phage-displayed single-chain variable fragment library and antibodies selected therefrom
CN114773466B (zh) * 2020-11-26 2023-08-29 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
CN114920845A (zh) * 2020-12-31 2022-08-19 中元汇吉生物技术股份有限公司 特异性结合人IgG4的蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
JP2646007B2 (ja) * 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
EP0365209A3 (en) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH07119238B2 (ja) * 1989-12-18 1995-12-20 小野薬品工業株式会社 ヒトインターロイキン―４に対するモノクローナル抗体および該抗体の利用方法
CA2071908C (en) * 1989-12-20 2002-04-30 Lata Ramanathan Antibody antagonists of human interleukin-4
JPH04141095A (ja) * 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
AU684041B2 (en) * 1992-02-19 1997-12-04 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
JPH06269663A (ja) * 1993-03-17 1994-09-27 Toyobo Co Ltd Ｃｄ４陽性細胞捕集材
WO2001009059A1 (en) * 1999-07-30 2001-02-08 Battelle Memorial Institute Glass-ceramic joining material and method of joining

Also Published As

Publication number Publication date
DE69434223D1 (de) 2005-02-10
EP0730609B1 (en) 2005-01-05
HUT75833A (en) 1997-05-28
JP2006333870A (ja) 2006-12-14
CZ69896A3 (en) 1996-10-16
BG63549B1 (bg) 2002-04-30
BG100480A (bg) 1996-12-31
BR9407575A (pt) 1996-07-16
KR100362340B1 (ko) 2003-02-26
PL180125B1 (pl) 2000-12-29
AU695726B2 (en) 1998-08-20
CZ295928B6 (cs) 2005-12-14
PL313491A1 (en) 1996-07-08
WO1995007301A1 (en) 1995-03-16
EP0730609A4 (en) 2000-05-10
JP2007045831A (ja) 2007-02-22
AP583A (en) 1997-04-14
HU222041B1 (hu) 2003-04-28
CA2171336A1 (en) 1995-03-16
JP2009191077A (ja) 2009-08-27
FI961083A0 (fi) 1996-03-07
ATE286510T1 (de) 2005-01-15
HU9600616D0 (en) 1996-05-28
JPH09502708A (ja) 1997-03-18
FI119733B (fi) 2009-02-27
NZ274338A (en) 1998-02-26
AP9600782A0 (en) 1996-04-30
NO960956D0 (no) 1996-03-07
FI961083A (fi) 1996-05-06
AU7834094A (en) 1995-03-27
DE69434223T2 (de) 2005-12-22
CA2171336C (en) 2011-06-21
SK33396A3 (en) 1996-10-02
EP0730609A1 (en) 1996-09-11
CN1473854A (zh) 2004-02-11
ES2236693T3 (es) 2005-07-16
SK285556B6 (sk) 2007-03-01
CN1133599A (zh) 1996-10-16
CN1105728C (zh) 2003-04-16
NO960956L (no) 1996-05-06

Similar Documents

Publication Publication Date Title
UA48940C2 (uk) Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
NL300787I1 (uk)
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
MY124219A (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
EE200000318A (et) Uudsed ühendid
NO954342L (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
NO930693L (no) Mometasonfuroatmonohydrat, fremgangsmaate for fremstillingav dette og farmasoeytiske preprater
DK250181A (da) Fremgangsmaade til fremstilling af vinblastinderivater
DE3478810D1 (en) Benzazocinone and benzazoninone derivatives, process for their preparation, pharmaceutical preparations containing these compounds, and their therapeutical use
IL103510A0 (en) Pharmaceutical compositions containing antibodies for causing immunosuppression
EP1749840A3 (en) Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
AU563650B2 (en) Pharmaceutical compositions of benzothiophene derivatives
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
HK1016017A1 (en) Gonococcal anti-idiotypic antibodies and methods and compositions using them
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
AU565799B2 (en) 4-oxothiazolidin-2-ylidene-acetamide derivatives